Abstracts tagged "natural killer (NK) cells"

Abstract Number: 019 • 2020 Pediatric Rheumatology Symposium
Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome
Mingce Zhang ¹, Remy Cron ¹, Devin Absher ², Prescott Atkinson ¹, W. Winn Chatham ¹ and Randy Cron¹, ¹University of Alabama at Birmingham, Birmingham, ²HudsonAlpha Institute for Biotechnology, Huntsville
Background/Purpose: Cytokine storm syndromes (CSS), such as macrophage activation syndrome (MAS) and secondary hemophagocytic lymphohistiocytosis (HLH), are life threatening conditions that commonly present with unremitting…
Abstract Number: 1295 • 2019 ACR/ARP Annual Meeting
Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells
Lauren Pachman¹, Wil Marin ², Gabrielle Morgan ¹, Megan L. Curran ³, Kaveh Ardalan ⁴, Chiang-Ching Huang ⁵ and Eli Roberson ⁶, ¹Northwestern University, Chicago, ²Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, IL, ³University of Colorado, Aurora, CO, ⁴Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵University of Milwaukee, Milwaukee, WI, ⁶Washington University at St.Louis, St.Louis, MO
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory myopathy in which the immunoregulatory control is not well understood. Collaboration with A.R. French, MD/PhD, documented the…
Abstract Number: 1926 • 2019 ACR/ARP Annual Meeting
Characterization of DOCK8 as a Novel Gene Associated with Macrophage Activation Syndrome
Mingce Zhang ¹, Remy Cron ², Devin Absher ³, Courtney Crayne ², Prescott Atkinson ², W. Winn Chatham ² and Randy Cron¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³HudsonAlpha Institute for Biotechnology, Huntsville, AL
Background/Purpose: Macrophage activation syndrome (MAS), also known as secondary hemophagocytic lymphohistiocytosis (HLH), is a life threatening condition that commonly presents with unremitting fever and shock…
Abstract Number: 2734 • 2019 ACR/ARP Annual Meeting
Signaling Lymphocytic Activation Molecule Family (SLAMF) Receptors Deregulation Is Implicated in the Altered Function of NK Cells in Systemic Lupus Erythematosus
Morgane Humbel ¹, Florence Bellanger ¹, Craig Fenwick ², Alice Horisberger ³, Camillo Ribi ³ and Denis Comte¹, ¹Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Epalinges, Vaud, Switzerland, ²Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Epalinhes, Vaud, Switzerland, ³Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Vaud, Switzerland
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by quantitative and qualitative deficiencies of immune cells. Natural killer (NK) cells are innate…
Abstract Number: 2805 • 2019 ACR/ARP Annual Meeting
Natural Killer Cells Gene Expression Can Differentiate Rheumatoid Arthritis Patients from Healthy Controls
Noha Elemam¹, Mahmood Hachim ¹, Suad Hannawi ² and Azzam Maghazachi ¹, ¹Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, Sharjah, United Arab Emirates, ²Ministry of Health and Prevention-UAE, Department of Rheumatology, Dubai, United Arab Emirates
Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent autoimmune diseases (1-3% of the world’s population). RA is a prototypic inflammatory disease, being characterized by an…
Abstract Number: 1020 • 2018 ACR/ARHP Annual Meeting
Involvement of Toll-like-Receptor-9 Pathway on Natural Killer Cells in Systemic Lupus Erythematosus
Micheline Pha¹, Samra Ouaras², Noel Zahr³, Melissa PLANTIER², Alexis Mathian⁴, Vincent Vieillard², Zahir Amoura⁵ and Baptiste Hervier^6,7, ¹Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²INSERM UMR-S 1135 & UPMC, Paris, France, ³Pitié Salpêtrière, Pharmacological, Pitié Salpêtrière, Paris, France, ⁴Université Pierre et Marie Curie, Sorbonne Paris Cité AP-HP, Service de Médecine Interne 2, Centre de Référence National pour le Lupus et le Syndrome des Antiphospholipides, institut E3M, Paris, France, Paris, France, ⁵Université Pierre et Marie Curie, Paris, France, ⁶INSERM UMR-1135 & UPMC, Paris, France, ⁷Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France
Background/Purpose: Natural killer (NK) cells participate in systemic lupus erythematosus (SLE) pathogenesis by promoting dendritic cell (DC) activation and/or interferon (IFN)g over-production. NK c ells…
Abstract Number: 1466 • 2018 ACR/ARHP Annual Meeting
Altered Count of NK Cells and Non-Classical Monocyte Subpopulation in the Pre-Clinical Phase of Rheumatoid Arthritis
Klára Prajzlerová¹, Olga Kryštůfková², Petra Hánová¹, Hana Hulejová³, Monika Gregová⁴, Karel Pavelka⁴, Jiri Vencovsky¹, Ladislav Šenolt⁵ and Mária Filková¹, ¹Department of Rheumatology, First Faculty of Medicine, Charles University and Rheumatology Institute, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, First Faculty of Medicine, Charles University and Rheumatology Institute, Prague, Czech Republic, prague, Czech Republic, ³Rheumatology Institute, Prague, Czech Republic, Prague, Czech Republic, ⁴Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are detectable long before the manifestation of rheumatoid arthritis (RA). EULAR provided a clinical definition of individuals with arthralgia suspicious…
Abstract Number: 2787 • 2018 ACR/ARHP Annual Meeting
−21 HLA-Class I Dimorphism Differentiates Psoriatic Arthritis (PsA) from Psoriasis without Psoriatic Arthritis (PsC)
Vinod Chandran¹, Quan Li², Rohan Machhar², Fatima Abji¹, Justine Y. Ye¹, Rajan Nair³, Philip Stuart³, Katerina Oikonomopoulou², James T. Elder⁴, Dafna D Gladman² and Proton Rahman⁵, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Michigan, Ann Arbor, MI, ⁴University of Michigan Medical School, Ann Arbor, MI, ⁵Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada
Background/Purpose: The association between human leukocyte antigen (HLA) class I alleles and psoriatic disease indicates a potential role for the innate immune system in disease…
Abstract Number: 2600 • 2016 ACR/ARHP Annual Meeting
Tofacitinib Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas
Gaetane Nocturne^1,2, Farhad Tahmasebi³, Saida Boudaoud⁴, Bineta Ly⁵ and Xavier Mariette^6,7, ¹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ²INSERM U1184, Université Paris Sud, Le Kremlin Bicêtre, France, ³INSERM 1184, Paris Sud University, Le Kremlin Bicetre, France, ⁴INSERM U1184, Paris Sud University, Le Kremlin Bicêtre, France, ⁵INSERM U1184, Paris Sud University, Kremlin Bicetre, France, ⁶Department of Rheumatology, APHP - Hopitaux universitaire Paris Sud, Le Kremlin Bicetre, France, ⁷INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France
Background/Purpose: Disease activity is the main risk factor for developing lymphoma in patients with rheumatoid arthritis (RA). However, the impact of immunosuppressive drugs remains an…
Abstract Number: 2868 • 2016 ACR/ARHP Annual Meeting
NK Cell Characterization in Patients with Systemic Lupus Erythematosus: Increased Frequency of Ki67+ NK Cells Associated with Disease Activity and Type I Interferon Signature
Kelly Hudspeth¹, Shu Wang², Jingya Wang², Saifur Rahman², Michael Smith², Kerry Casey², Geoffrey Stephens³, Miguel Sanjuan², Autoimmunity Molecular Medicine group², Zerai G. Manna⁴, Sarfaraz Hasni⁴, Rachel Ettinger⁵ and Richard Siegel⁶, ¹Immunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Respiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, ³Respiratory, Inflammatory, and Autoimmune Diseases Research, Medimmune, LLC, Gaithersburg, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Respiratory, Inflammation and Autoimmunity (RIA), MedImmune, LLC, Gaithersburg, MD, ⁶Immunoregulation Section, Autoimmunity Branch and Office of the Clinical Director National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder whose pathology appears to involve many immune cell types. While it is clear that autoantibody…
Abstract Number: 1112 • 2015 ACR/ARHP Annual Meeting
Obinutuzumab Outperforms Rituximab at Inducing B-Cell Cytotoxicity in Vitro through Fc-Mediated Effector Mechanisms in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Venkat Reddy¹, Christian Klein², David A. Isenberg³, Geraldine Cambridge⁴, Martin Glennie⁵, Mark Cragg⁶ and Maria J. Leandro¹, ¹Rheumatology, University College London, London, United Kingdom, ²Roche Pharmaceutical Research & Early Development Oncology Discovery & Translational Area, Roche Glycart AG, Schlieren, Switzerland, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ⁴Rheumatology, Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, London, United Kingdom, ⁵Antibody and Vaccine group, Southampton University, Southampton, United Kingdom, ⁶Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom
Background/Purpose: Obinutuzumab (OBZ, a Type II anti-CD20 monoclonal antibody [mAb] with afucosylated Fc portion and enhanced affinity for Fcγ receptor III) is more efficient than…
Abstract Number: 2831 • 2015 ACR/ARHP Annual Meeting
A Subset of Natural Killer Cells Are Expanded in Synovial Fluid of Patients with Reactive Arthritis and Undifferentiated Spondyloarthritis
Abhra Chandra Chowdhury, Smriti Chaurasia, Amita Aggarwal and Ramnath Misra, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: We have previously shown that there is an increase in IL-17 in the synovial fluid of patients with Reactive arthritis(ReA) and undifferentiated spondyloarthropathy(uSpA). Besides…
Abstract Number: 2178 • 2014 ACR/ARHP Annual Meeting
Extensive Natural Killer Cell Receptor Phenotyping on NK and T Cells Discloses Differences in RA and Psa, Potentially Mirroring Diverse Immunoregulatory Functions
Marta Cossu¹, Sandra TA van Bijnen², Mieke Roeven², Tim Jansen³, Frank Preijers⁴, Harry Dolstra⁴ and Timothy Radstake⁵, ¹Department of Rheumatology, Clinical Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Hematology, Radboud University Medical Center, Nijmegen, Netherlands, ³Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁴Laboratory Medicine-Laboratory of Hematology, Radboud University Medical Center, Nijmegen, Netherlands, ⁵Rheumatology, Clinical Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are immune-mediated diseases, which share clinical features, but differ in the mechanisms, leading to aberrant immune responses.…
Abstract Number: 1459 • 2014 ACR/ARHP Annual Meeting
IL-22 Secreted By NKp44+NK Cells Promote the Proliferation of Synovium in Patients with Rheumatoid Arthritis By Activation of STAT3
Junqing Zhu¹, Juan Li¹ and Xiaoguang Chen², ¹Nanfang Hospital, College of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China, ²School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China
Background/Purpose: Although CD3-CD56+NKp44+ natural Killer cells (NKp44+NK cells) have been linked to autoimmune diseases including inflammatory bowel disease, ankylosing spondylitis, and primary Sjogren's syndrome, the…
Abstract Number: 508 • 2014 ACR/ARHP Annual Meeting
Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib
R. van Vollenhoven¹, Y. Tanaka², R. Riese³, M. Lamba³, T. Kawabata³, T. Hirose⁴, S. Toyoizumi⁴, A. Hazra³ and S. Krishnaswami³, ¹The Karolinska Institute, Stockholm, Sweden, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Tokyo, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines (e.g. interleukin [IL]-2, -4, -7, -15, -21) involved…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].